{"id":23601,"date":"2024-11-07T08:59:59","date_gmt":"2024-11-07T13:59:59","guid":{"rendered":"https:\/\/medicarereport.org\/?p=23601"},"modified":"2024-11-07T09:00:03","modified_gmt":"2024-11-07T14:00:03","slug":"fda-adds-warning-to-ozempic-mounjaro-and-other-glp-1-labels","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=23601","title":{"rendered":"FDA adds warning to Ozempic, Mounjaro and other GLP-1 labels"},"content":{"rendered":"\n<p>(By Alexandra Murphy for <em>Becker&#8217;s Hospital Review<\/em>)<\/p>\n\n\n\n<p>The FDA has updated the labels for all GLP-1 receptor agonists, including popular medications Ozempic, Wegovy, Saxenda and Mounjaro, to include a new warning about the risk of pulmonary aspiration during general anesthesia or deep sedation, Medscape reported Nov. 6.  Continue reading <a href=\"https:\/\/www.beckershospitalreview.com\/pharmacy\/fda-adds-warning-to-ozempic-mounjaro-and-other-glp-1-labels.html\" data-type=\"link\" data-id=\"https:\/\/www.beckershospitalreview.com\/pharmacy\/fda-adds-warning-to-ozempic-mounjaro-and-other-glp-1-labels.html\">here&#8230;<\/a><\/p>\n\n\n\n<p><img loading=\"lazy\" decoding=\"async\" width=\"200\" height=\"65\" class=\"wp-image-7881\" style=\"width: 200px;\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/FDA-logo.jpg\" alt=\"\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/FDA-logo.jpg 322w, https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/08\/FDA-logo-300x97.jpg 300w\" sizes=\"auto, (max-width: 200px) 100vw, 200px\" \/><\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>Notice:<\/strong>\u00a0The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Alexandra Murphy for Becker&#8217;s Hospital Review) The FDA has updated the labels for all GLP-1 receptor agonists, including popular<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31,15],"tags":[76,1468,1321,504],"class_list":["post-23601","post","type-post","status-publish","format-standard","hentry","category-fda","category-part-dprescription-drugs","tag-fda","tag-glp-1-drugs","tag-mounjaro","tag-ozempic"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/23601","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23601"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/23601\/revisions"}],"predecessor-version":[{"id":23602,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/23601\/revisions\/23602"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}